What is Day One Biopharmaceuticals Financial Strength?
Day One Biopharmaceuticals has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.
Good Sign:
Day One Biopharmaceuticals Inc shows strong financial strength.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Day One Biopharmaceuticals has no long-term debt (1).
As of today, Day One Biopharmaceuticals's Altman Z-Score is 0.00.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Competitive Comparison of Day One Biopharmaceuticals's Financial Strength
For the Biotechnology subindustry, Day One Biopharmaceuticals's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Day One Biopharmaceuticals's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Day One Biopharmaceuticals's Financial Strength distribution charts can be found below:
* The bar in red indicates where Day One Biopharmaceuticals's Financial Strength falls into.
Day One Biopharmaceuticals Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Day One Biopharmaceuticals's Interest Expense for the
months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the
months ended in Dec. 2023 was $-59.52 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil.
Day One Biopharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2023 is
| Day One Biopharmaceuticals had no long-term debt (1). |
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Day One Biopharmaceuticals Inc has enough cash to cover all of its debt. Its financial situation is stable.
2. Debt to revenue ratio. The lower, the better.
Day One Biopharmaceuticals's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Day One Biopharmaceuticals has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Day One Biopharmaceuticals (Day One Biopharmaceuticals) Business Description
Traded in Other Exchanges
N/A
Address
2000 Sierra Point Parkway, Suite 501, Brisbane, CA, USA, 94005
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The lead product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
Executives
| York Charles N Ii |
officer: COO, CFO and Secretary |
901 S. MOPAC EXPRESSWAY, BARTON OAKS PLAZA ONE, SUITE 250, AUSTIN TX 78746 |
| Samuel C. Blackman |
officer: Chief Medical Officer |
395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080 |
| Jeremy Bender |
director, officer: Chief Executive Officer |
395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080 |
| Ai Day 1 Llc |
10 percent owner |
40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019 |
| Julie Papanek Grant |
director |
2765 SAND HILL ROAD, MENLO PARK CA 94025 |
| Canaan Xi L.p. |
10 percent owner |
2765 SAND HILL RD, MENLO PARK CA 94025 |
| Garry A Nicholson |
director |
C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451 |
| Atlas Venture Opportunity Fund Ii, L.p. |
10 percent owner |
300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139 |
| Michael Gladstone |
director |
395 OYSTER POINT BLVD, SUITE 217, SOUTH SAN FRANCISCO CA 94080 |
| Atlas Venture Fund Xi, L.p. |
10 percent owner |
400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
| Takeda Pharmaceutical Co Ltd |
10 percent owner |
1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668 |
| Takeda Pharmaceuticals U.s.a., Inc. |
10 percent owner |
ONE TAKEDA PARKWAY, DEERFIELD IL 60015 |
| Takeda Ventures, Inc. |
10 percent owner |
9625 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121 |
| J. Scott Garland |
director |
210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
| John A. Josey |
director |
C/O PELOTON THERAPEUTICS, INC., 2330 INWOOD ROAD, SUITE 226, DALLAS TX 75235 |
Day One Biopharmaceuticals (Day One Biopharmaceuticals) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DAWN has been successfully added to your